Denali Therapeutics Inc. DNLI
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -314.42M | -511.45M | -508.02M | -512.54M | -498.74M |
| Total Depreciation and Amortization | 16.52M | 15.89M | 15.36M | 14.81M | 13.65M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -100.77M | 89.84M | 85.73M | 84.98M | 81.63M |
| Change in Net Operating Assets | -45.51M | -28.32M | -5.41M | 149.00K | 5.69M |
| Cash from Operations | -444.19M | -434.04M | -412.34M | -412.60M | -397.78M |
| Capital Expenditure | -5.81M | -3.42M | -6.89M | -9.50M | -13.07M |
| Sale of Property, Plant, and Equipment | 194.00M | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -160.85M | 72.40M | 337.88M | 264.78M | 419.79M |
| Cash from Investing | 27.34M | 68.98M | 330.99M | 255.28M | 406.72M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -76.00K | -1.42M | -3.83M | -8.17M | -16.48M |
| Issuance of Common Stock | 957.20M | 955.12M | 944.17M | 925.71M | 9.39M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -528.37M | -528.32M | -528.32M | -728.32M | 0.00 |
| Cash from Financing | 428.75M | 425.38M | 412.02M | 189.22M | -7.09M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.91M | 60.32M | 330.68M | 31.90M | 1.86M |